Focus Partners Wealth
AKBA icon

Focus Partners Wealth’s Akebia Therapeutics AKBA Stock Holding History

Focus Partners Wealth’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.3K Buy
80,948
+51,115
+171% +$60.9K ﹤0.01% 2629
2026
Q1 		$41.5K Sell
29,833
-16,867
-36% -$23.2K ﹤0.01% 2589
2025
Q4 		$75.2K Buy
46,700
+16,109
+53% +$33.7K ﹤0.01% 2577
2025
Q3 		$86.5K Buy
30,591
+17,324
+131% +$57.6K ﹤0.01% 2137
2025
Q2 		$48.3K Buy
13,267
+1,876
+16% +$5.16K ﹤0.01% 1978
2025
Q1 		$21.2K Buy
11,391
+499
+5% +$1.02K ﹤0.01% 1872
2024
Q4 		$20.7K Buy
+10,892
New +$18.9K ﹤0.01% 1847
2024
Q3 		– Sell
-10,575
Closed -$14K – 1570
2024
Q2 		$14K Buy
10,575
+37
+0.4% +$46 ﹤0.01% 1222
2024
Q1 		$13K Buy
+10,538
New +$16.8K ﹤0.01% 978

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Focus Partners Wealth's AKBA Position: Q2 2026 in Review

Focus Partners Wealth increased its Akebia Therapeutics (AKBA) stake by 171% in Q2 2026, buying an estimated $60.9K and bringing the position to 80,948 shares worth $92.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2629.

Focus Partners Wealth first reported a position in AKBA in Q1 2024 and has held it in 9 quarters since. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Focus Partners Wealth held 80,948 shares of Akebia Therapeutics worth $92.3K as of Q2 2026.
  • Focus Partners Wealth bought 51,115 Akebia Therapeutics shares in Q2 2026, an estimated $60.9K.
  • Akebia Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2629 holding.
  • Focus Partners Wealth first reported a position in Akebia Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.